European Society for Medical Oncology: No Clinical Benefit from Nivolumab Plus Ipilimumab Over Nivolumab Alone as First-Line Treatment of Recurrent or Metastatic Squamous Cell Carcinoma of Head and Neck

Press/Media

Period	14 Apr 2023

Media coverage

Title	European Society for Medical Oncology: No Clinical Benefit from Nivolumab Plus Ipilimumab Over Nivolumab Alone as First-Line Treatment of Recurrent or Metastatic Squamous Cell Carcinoma of Head and Neck
Media name/outlet	India Pharma News
Country/Territory	India
Date	14/04/23
URL	ct.moreover.com/?a=50523885394&p=1gw&v=1&x=cbsiXcDpz9UleNZsUbaKmQ
Persons	Marshall Posner